Advice
Search strategy and evidence selection
Search strategy
For the clinical evidence
Ovid MEDLINE(R) 1946 to January Week 1 2016, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations January 18, 2016.
-
1. prolaris.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
2. cell cycle progression.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
3. ccp score.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
-
4. ccp test.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
5. gene expression assay.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
6. myriad genetics.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
7. prostate cancer.mp. or Prostatic Neoplasms/
-
8. 1 or 2 or 3 or 4 or 5
-
9. 7 and 8
-
10. limit 9 to (english language and yr="2010 -Current")
-
11. remove duplicates from 10
Embase 1980 to 2016 Week 03 January 18, 2016.
-
1. prolaris.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
2. cell cycle progression score.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
3. cell cycle progression .mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
-
4. ccp score.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
5. ccp test.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
-
6. gene expression assay.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
7. myriad genetics.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
7. prostate cancer/
-
8. 1 or 2 or 3 or 4 or 5 or 6
-
9. 7 and 8
-
10. limit 9 to (english language and yr="2010 -Current")
For the economic evidence
Ovid MEDLINE(R) 1946 to January Week 2 2016, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations January 25, 2016
-
prolaris.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
cell cycle progression.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
ccp score.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
ccp test.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
-
gene expression assay.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
myriad genetics.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
prostate cancer.mp. or Prostatic Neoplasms/
-
1 or 2 or 3 or 4 or 5 or 6
-
7 and 8
-
cost.mp. or "Costs and Cost Analysis"/
-
economic.mp
-
10 or 11
-
9 and 12
-
limit 13 to (english language and yr="2010-current")
Embase 1980 to 2016 Week 04
-
prolaris.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
cell cycle progression.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
ccp score.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
ccp test.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
-
gene expression assay.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
myriad genetics.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
-
prostate cancer/
-
1 or 2 or 3 or 4 or 5 or 6
-
7 and 8
-
"cost benefit analysis"/ or "cost minimization analysis"/ or cost.mp. or "cost"/ or "cost effectiveness analysis"/
-
economic.mp
-
10 or 11
-
9 and 12
-
limit 13 to (english language and yr="2010-current")
Cochrane Database of Systematic Reviews: Issue 1 of 12, January 2016
Cochrane Central Register of Controlled Trials: Issue 12 of 12, December 2015
Database of Abstracts of Reviews of Effect: Issue 2 of 4, April 2015
Health Technology Assessment Database: Issue 4 of 4, October 2015
NHS Economic Evaluation Database: Issue 2 of 4, April 2015
Cochrane Methodology Register: Issue 3 of 4, July 2012
Evidence selection
For the clinical evidence
-
Total number of publications reviewed: 71
-
Total number of publications considered relevant: 19
-
Total number of publications selected for inclusion in this briefing: 9
Shore et al. 2016 has been included instead of Shore et al. 2014 as this provides better quality evidence for the effect of Prolaris on change in treatment. Shore et al. 2014 is a relatively small study in terms of number of clinicians and is based on intention. Shore et al. 2016 evaluates actual treatment decisions so has more weight.